NAPROXEN SODIUM CAPLETS TABLET
Valsts: Kanāda
Valoda: angļu
Klimata pārmaiņas: Health Canada
Produkta apraksts
(SPC)
31-01-2012
Daži šī produkta dokumenti pašlaik nav pieejami. Varat nosūtīt pieprasījumu mūsu klientu apkalpošanas dienestam, un mēs jums paziņosim, tiklīdz mēs tos varēsim iegūt.
Nosūtīt pieprasījumu.
Nosūtīt pieprasījumu.
Aktīvā sastāvdaļa:
NAPROXEN SODIUM
Pieejams no:
VITA HEALTH PRODUCTS INC
ATĶ kods:
M01AE02
SNN (starptautisko nepatentēto nosaukumu):
NAPROXEN
Deva:
220MG
Zāļu forma:
TABLET
Kompozīcija:
NAPROXEN SODIUM 220MG
Ievadīšanas:
ORAL
Vienības iepakojumā:
100
Receptes veids:
OTC
Ārstniecības joma:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Produktu pārskats:
Active ingredient group (AIG) number: 0113934003; AHFS:
Autorizācija statuss:
APPROVED
Autorizācija datums:
2012-01-30
Produkta apraksts
_Page 1 of 35_
PRODUCT MONOGRAPH
NAPROXEN SODIUM TABLETS
NAPROXEN SODIUM CAPLETS
NAPROXEN SODIUM TABLETS USP, 220 MG
Non-steroidal anti-inflammatory drug
Analgesic, Antipyretic
Vita Health Products Inc.
150 Beghin Avenue, Winnipeg
Manitoba, Canada R2J 3W2
Date of Preparation:
January 26, 2012
Control No.: 134246
_Page 2 of 35_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.............................................................................3
SUMMARY PRODUCT INFORMATION
.............................................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................................
3
CONTRAINDICATIONS
........................................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................................
4
ADVERSE REACTIONS
.........................................................................................................................
6
DRUG INTERACTIONS
.........................................................................................................................
9
DOSAGE AND ADMINISTRATION
...................................................................................................11
OVERDOSAGE
.....................................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
..................................................................................12
STORAGE AND STABILITY
...............................................................................................................13
SPECIAL HANDLING INSTRUCTIONS
............................................................................................13
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................................14
PART II:
Izlasiet visu dokumentu
